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Abstract
Rationale/Objectives—Smoking has been associated with decreased incidence and prevalence
of sarcoidosis, but few studies have evaluated effects of smoking on clinical parameters of the
disease. The objectives were to determine the association of smoking with radiographic patterns
and to evaluate the associations of these smoking-related radiographic patterns on airflow
obstruction in sarcoidosis.
Methods—Clinical data and CT scans of 124 patients with sarcoidosis were reviewed. CT scans
were assessed for lymph nodes, nodules, bronchiectasis, bronchovascular bundle thickening,
displaced hilum, fibrosis, ground glass, emphysema, pleural changes, and alveolar opacities. CT
patterns were compared between patients with and without a history of smoking. The effect of
smoking on the associations between radiographic patterns and airflow obstruction was assessed
with multivariable analysis.
Results—Smokers had less frequency of bronchovascular bundle thickening than nonsmokers
(11/38 subjects(29%) vs. 50/86 subjects(58%),p=0.003) and more emphysema (7/38
subjects(18%) vs. 1/86 subjects(1%),p=0.001). Patients who had bronchovascular bundle
thickening were less likely to have ever smoked (11/61 subjects(18%) vs. 27/63 subjects(43%),
p=0.003) or be current smokers (4/61 subjects(7%) vs. 15/63 subjects(24%),p=0.008). Age
(p=0.003) and bronchovascular bundle thickening (p=0.02) were independent predictors of airflow
obstruction. There were no differences in smoking history between patients with airflow
obstruction versus those without (10/37 subjects(27)% vs. 28/87 subjects(32%),p=0.63).
Conclusions—In patients with sarcoidosis, smoking is associated with decreased frequency of
bronchovascular bundle thickening, a very important clinical manifestation of the lung disease.
© 2011 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.
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Further, bronchovascular bundle thickening and age are the only independent predictors of airflow
obstruction, and smoking does not confound these associations.
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INTRODUCTION
Sarcoidosis is an inflammatory disease of unknown etiology predominately affecting the
lungs. Noncaseating granulomas are the hallmark of the disease, and can cause decreased
pulmonary function, impairment of gas exchange, and fibrosis of lung parenchyma. The
natural history of the disease is not completely understood, adding complexity to clinical
management and treatment.1 Thus, further study of clinical parameters is warranted.
Multiple epidemiologic studies have found smoking to be associated with decreased
incidence and prevalence of the disease.2-5 A case control etiologic study of sarcoidosis
(ACCESS) showed that smoking subjects were less likely to have sarcoidosis (OR 0.62, CI
0.5-0.77), and Visser et al. found that patients presenting with sarcoid arthritis were much
less likely to be smoking (OR 0.09, CI 0.02-0.37).6,7 However, there are few studies that
have evaluated the effect of smoking on patients who have sarcoidosis. For instance, two
descriptive studies of sarcoidosis populations have not indicated that smoking affects
progression or severity of disease, or that smoking prevents respiratory failure in this
group.3,8,9 The mechanisms behind this paradoxical phenomenon (decreased incidence, but
no effect on disease severity) are unclear, and the question of how smoking has an overall
effect on sarcoidosis remains unanswered.
In this study, the objective was to evaluate the effects of smoking on clinical parameters of
the disease. First, we analyzed high resolution CT scans of sarcoidosis patients to determine
differences in radiographic patterns between smokers and nonsmokers. Second, we
evaluated the effect of these smoking-associated radiographic patterns on obstructive
sarcoidosis lung disease.
METHODS
A chart review was performed on 275 adult patients (ages 18-75) diagnosed with pulmonary
sarcoidosis between 2001 and 2007. Patients were included if they had been evaluated by a
pulmonary physician and had a diagnosis of sarcoidosis with a consistent clinical
presentation and a biopsy showing noncaseating granulomas. Each patient was required to
have spirometry and CT scan imaging of the chest within 30 days of each other and
available for review. Patients were excluded if there was a diagnosis of an alternative cause
of granulomatous disease such as histoplasmosis, silicosis, berylliosis, malignancy, or talc-
induced granulomas. One hundred and twenty-four patients fulfilled these criteria. The
primary reason for exclusion was lack of CT data within thirty days of lung function testing.
Due to retrospective review, the indications for CT scans were not available. Other data
collected included race, age, gender, smoking history, organ involvement (other than lung),
reported asthma and obstructive sleep apnea history, and treatment history.
CT Scans
CT scans (Siemens, USA) were performed using a volume scan and high resolution
reconstruction algorithm at 1 mm and 3 mm slice thickness. These were independently
reviewed by two pulmonologists with expertise in sarcoidosis and a chest radiologist for the
presence or absence of lymph nodes, nodules, ground glass changes, thickened
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bronchovascular bundles, bronchiectasis, displaced hilum, fibrosis, emphysema, alveolar
consolidation, or pleural changes. Differences in readings were adjudicated after discussion
between the examiners. Kappa scores calculated for the primary finding of bronchovascular
bundle thickening prior to adjudication indicated good to very good agreement (kappa range
0.65 to 0.83) between the three examiners. The examiners were blinded to the clinical data
of smoking status, pulmonary function tests, and prior CT readings.
Pulmonary Function Tests
Pulmonary function tests were performed using the American Thoracic Society guidelines.10
FVC, FEV1, and FEV1/FVC prior to bronchodilators were recorded for each patient.
Obstructive lung disease was defined as an FEV1/FVC ratio less than 70%. Total lung
capacity (TLC) and diffusing capacity (DLco) were also recorded. Pulmonary function
results are reported as percentages of predicted values.
Analysis
Tests of normality (Shapiro-Wilk tests) were performed prior to comparisons of continuous
data. Age, FVC, FEV1, and TLC were presented as means with standard deviations (SD),
while FEV1/FVC and DLco were presented as medians with interquartile range (IQR).
Student’s T-tests were performed for comparisons of normally distributed data, while
Wilcoxon rank sum tests were performed for data that were not normally distributed.
Comparisons of categorical data were evaluated using Pearson chi-square tests or Fisher’s
exact tests depending on frequency of occurrence. To evaluate the effect of smoking on the
relationship between radiographic patterns and obstructive lung disease, stepwise logistic
regression analysis was used initially to establish independent predictors of obstruction.
Radiographic patterns that were significant at p=0.1 level in the univariate analysis were
entered as covariates and kept in the model if significant at p<0.05. Based on this analysis, a
final logistic regression model was established, which included age, smoking status, race,
and bronchovascular bundle thickening as covariates. Linearity of age was examined by
fitting a logistic regression model where the variable age was categorized based on quartiles
using the lowest quartile as reference. The estimates corresponding to each age category
were plotted against the midpoint of each interval. From this, we concluded that age was a
linear effect and kept it as a continuous variable. P-values of <0.05 were considered
statistically significant. Kappa analysis was performed to assess interobserver variability.
All analyses were performed using SAS 9.2 statistical package (SAS, Cary, North Carolina).
This study was approved by the Institutional Review Board (Approval #200702715).
RESULTS
Patient Characteristics
The study included 124 patients with pulmonary sarcoidosis. Demographic characteristics,
smoking status, systemic and inhaled treatment histories, pulmonary function, and CT
findings are described in Table 1. Ninety-four (76%) of patients underwent systemic
treatment. The indication for treatment was pulmonary disease in 49 patients (52% of those
treated) and organ-threatening extrapulmonary disease in 45 patients (48% of those treated).
Of patients treated with systemic medications, the CT scans were obtained prior to treatment
in 35%, during treatment in 36%, and after completion of treatment in 15% of patients. The
most common CT findings were bronchovascular bundle thickening (Figure 1),
lymphadenopathy, and nodules.
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Comparison of Smokers versus Non-smokers
Findings between smokers and nonsmokers are summarized in Table 2. The only significant
differences between smokers and nonsmokers on lung CT were the frequencies of
bronchovascular bundle thickening and emphysema. Patients who smoked were more likely
to be younger (42 years vs. 48 years, p=0.01) and African-American (26% vs. 10%, p=0.03).
The median pack-year smoking history was 10 pack-years for subjects who had ever smoked
(IQR 5-30), and was also 10 pack-years for both ex-smokers (IQR 5-30), and current
smokers (IQR 7-30). The median time from smoking cessation to CT scan was 9.0 years
(IQR 1-15). In the subgroup of ten people with a smoking history who were obstructed,
three had thickened bronchovascular bundles and three had emphysema. Smoking was not
associated with the prevalence of obstructive lung disease in this population.
Similarly, patients who had bronchovascular bundle thickening were less likely than patients
without bronchovascular bundle thickening to have ever smoked or be current active
smokers and were more likely to have associated CT patterns of nodules (89% vs. 46%,
p<0.0001), fibrosis (39% vs. 13%, p=0.0007), and displaced hilum (21% vs. 2%, p=0.0005)
(Table 3).
CT Findings in Patients with Airflow Obstruction
The demographics, pulmonary function, smoking history, treatment histories, and
frequencies of CT findings in obstructed versus non-obstructed patients are summarized in
Table 4. Multivariate logistic regression modeling, including race and smoking status as
covariates, revealed age (OR: 1.06 per year of age, 95% CI: 1.02-1.11, p=0.003) and
bronchovascular bundle thickening (OR 3.28, 95%CI 1.31-8.22, p=0.02) to be
independently associated with obstructive lung disease in sarcoidosis patients. These effects
of bronchovascular bundle thickening was similar to that found in a model without smoking
history (OR: 2.74, 95% CI: 1.17-6.38). Thus, a history of smoking did not confound these
effects.
DISCUSSION
In this study, analysis revealed that patients with sarcoidosis with a history of smoking had a
significant decrease in frequency of bronchovascular bundle thickening compared with
nonsmokers with sarcoidosis. Further, a history of smoking was not predictive for
obstructive lung disease in this population. Rather, age and bronchovascular bundle
thickening were the primary determinants of airflow obstruction in a population of patients
diagnosed with sarcoidosis.
The bronchovascular bundles are made up of the bronchi and accompanying pulmonary
arteries which extend out radially from the hila of the lungs. Bronchovascular bundle
thickening on CT scans refers to the appearance of branching lines with a beaded
appearance along a peri-bronchovascular distribution.11 Previous data have shown that
radiographic findings correlate to pathologic findings in patients with sarcoidosis.12 Our
data suggest that granulomas along the airways and lymphatic vessels, as seen on CT as
thickened bundles, are less frequent in those patients with a smoking history. The effect is
apparent in patients who were ex-smokers and in those who currently smoke.
This is the first study to show an effect of smoking on bronchovascular bundle thickening.
However, the idea that smoking may affect expression of the disease has been previously
surmised due to a number of prior epidemiologic studies indicating decreased incidence and
prevalence in smokers. The largest case control study to date (ACCESS) found that the odds
of sarcoidosis risk in patients who ever smoked was significantly lower (OR 0.65, CI
0.51-0.82, p<0.001).6 Our data provide a biologic correlate to this epidemiologic data, and
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show that smoking also suppresses important indicators of disease in patient who already
have sarcoidosis. Smoking has also been shown to have an effect on development of
hypersensitivity pneumonitis, another granulomatous disease, although this effect cannot be
generalized to all granulomatous diseases.13,14
Patho-physiologically, it has been suggested that smoking may decrease inflammatory
cytokines that contribute to formation of granulomas.15 Tobacco smoke decreases the
release of TNF-alpha by alveolar macrophages in normal subjects and in those with
sarcoidosis.16 Similarly, nicotine has been shown to inhibit the formation of granulomas in
hypersensitivity pneumonitis in a murine model.17 Further, smokers with sarcoidosis have
decreased alveolitis and decreased CD4:CD8 ratio as compared to nonsmoking sarcoidosis
patients.4,18 Our findings support cellular and animal model evidence of the effect of
cigarette smoke on disease expression, providing further translational evidence of an effect
in human subjects. It is currently unclear whether these effects are due to nicotine alone, or
rather, one of the many components of tobacco smoke.
Previous authors have suggested that smoking has no effect on the extent, severity, or course
of disease.9,19 However, these studies did not utilize CT imaging in the methods, and this
study is the first to methodologically assess these parameters. Although this study was not
designed to assess prognosis, the marked effect of smoking on the presence of
bronchovascular bundles on CT scans warrants further inspection of this phenomenon. If
bronchovascular bundle thickening is a surrogate marker for airway obstruction or burden of
granulomas in the airway, it could have implications for this disease. The effect of smoking
may be more pronounced in early stages, particularly if the effects are due to changes in
macrophage and lymphocyte function during development of the disease or in clearing a
potential antigen exposure. Perhaps, as other studies have noted, there is no difference in
prognosis between smokers and nonsmokers with sarcoidosis because smoking introduces as
second insult on the lung that also contributes to the overall burden of lung disease and its
prognosis, as clearly, emphysema is more prevalent in these patients.
It is also important to note that smoking was not independently associated with obstruction,
which is likely related to the relatively young age of the population with a low prevalence of
chronic obstructive pulmonary disease and emphysema. In addition, similar observations
have also been noted in patients with both emphysema and pulmonary fibrosis.20,21 It is
likely that the presence of a parenchymal lung disease that causes lung restriction decreases
the obstruction associated with emphysema because of its effect on elastic recoil of the lung.
Radiographically, only eight subjects (6%) had evidence of emphysema in our study.
One previous study has shown that airflow obstruction in sarcoidosis is most strongly
associated with smoking history and emphysema, and a correlation between the CT pattern
of air trapping and obstruction occurred only in smokers.22 A study in Japanese patients
indicated that age, bronchovascular bundle thickening, chest radiographic stage IV
(suggestive of pulmonary fibrosis), and smoking are associated with a lower FEV1/FVC,
although multivariate analysis was limited by low frequencies of airway obstruction and
bronchovascular bundle thickening in the population.23 Only five patients with airflow
obstruction had bronchovascular bundle thickening. Thus, it was not clear from this study
which of these parameters was the primary determinant of obstruction. Our population
includes a markedly higher frequency of obstructive lung disease and abnormal lung CT
findings, and shows that bronchovascular bundle thickening and age are the main predictors
of obstruction. Hansell et al. also described CT patterns in 45 patients with sarcoidosis and
found that reticular patterns reflective of fibrosis were associated with airflow obstruction
when compared with mosaic pattern, ground-glass opacities, nodules, or intense
opacification with or without air bronchograms.24 Bronchovascular bundle thickening was
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not evaluated in that study. If bronchovascular bundle thickening had not been included in
our study, the results would have resembled those of Hansell et al.
The strength of our study is that it includes a large number of patients in order to determine
the influence of smoking on the interpretation of lung function and imaging results in
sarcoidosis. For practical clinical purposes, these data emphasize that obstructive lung
physiology should not automatically be attributed to smoking in patients with sarcoidosis, as
subjects in this subgroup had an equally likely chance of having either bronchovascular
bundle thickening or emphysema. Although smoking was not found to be a predictor, age
was associated with obstruction. This factor appeared to be independent and did not interact
with any particular CT pattern. This implies that bronchovascular bundle thickening may be
driving the obstruction in sarcoidosis, but age is also contributing independently to the risk
of obstruction. This may reflect an expected physiologic reaction to age.
Limitations exist due to the observational nature of this study. The percentage of airflow
obstruction is high compared to the ACCESS study (30% versus 14%, respectively) and all
subjects were required to have had a CT scan. In terms of patient characteristics, data was
not available regarding alternative comorbidities that may also contribute to parenchymal
findings and obstructive lung disease, and symptom severity was not available to incorporate
into the analysis. The indications for the CT scans were not known which could have
introduced selection bias in the study population. It is possible that only the most severe
manifestations of the disease were selected in nonsmokers, whereas there was more liberal
use of CT scanning in smokers to differentiate symptoms related to smoking related lung
disease versus sarcoidosis that led to selection of less severe cases. The low incidence of
emphysema in the population would suggest that this bias, if present, is rather small.
Further, we were not able to study the interacting effects of race and smoking, given the
demographics and low percentage of African-Americans in the referral population of this
region. Another potential limitation is that the CT scans were performed over a seven year
period which could have introduced variation in technique. However, all were high
resolution scans performed on the same brand of CT scanner, and each was read with similar
thickness of slice cuts.
In conclusion, the effects of smoking on sarcoidosis have now been shown in two ways: 1)
the ACCESS study showed that smoking was associated with lower overall expression of
sarcoidosis, and 2) this study shows that, in patients with sarcoidosis, smoking decreases a
very important clinical manifestation of the lung disease, i.e. bronchovascular bundle
thickening. In our study, this lung CT finding was strongly associated with airway
obstruction. These associations cannot be deemed causal at this point, as the exact
mechanisms behind this phenomenon are not delineated. It does, however, raise the question
of whether smoking inhibits the immune response that leads to the formation of granulomas
in sarcoidosis. Further study regarding this process may give further insight into
mechanisms and development of this disease.
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FEV1 Forced expiratory volume in one second
FVC Forced vital capacity
TLC Total Lung Capacity
DLco Diffusing Capacity
SD Standard deviation
IQR Interquartile range
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Figure 1.
Bronchovascular bundle thickening in sarcoidosis. An example of a subject with severe
bronchovascular bundle thickening in the right lung and more subtle thickening in the left
(arrows).
Gerke et al. Page 9
Acad Radiol. Author manuscript; available in PMC 2012 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Gerke et al. Page 10
Table 1
Patient characteristics and CT findings
Variable Population (n=124)
Age (years) * 45 (11) (range 16-75)
Gender
  Female 82 (66%)
Race
  African-American 19 (15%)
  Caucasian 105 (85%)
Smoking Status
  Never Smoked 86 (69%)
  Ever Smoked (Past or Active) 38 (31%)
  Active Smoker 20 (16%)
Obstructive Lung Disease 37 (30%)
Pulmonary Function (%) *
  FVC 85 (19)
  FEV1 83 (22)
  FEV1/FVC 75 (67-80)
  TLC 89 (18)
  DLco 75 (64-85)
Asthma History 16 (13%)
Obstructive Sleep Apnea 16 (13%)
Systemic Treatment History 94 (76%)
  Prednisone therapy 87 (70%)
  Methotrexate 59 (48%)
Reason for Treatment
  Pulmonary Disease 49 (40%)
  Extrapulmonary Disease 45 (36%)
Inhaled Therapies 51 (41%)
  Corticosteroid Inhaler Only 13 (10%)
  Bronchodilator Inhaler Only 12 (10%)
  Steroid and Bronchodilator 26 (21%)
CT Findings
  Lymph Nodes 111 (90%)
  Nodules 83 (67%)
  BVB Thickening 61 (49%)
  Fibrosis 32 (26%)
  Bronchiectasis 29 (23%)
  Ground Glass 23 (19%)
  Alveolar Opacities 15 (12%)
  Displaced Hilum 14 (11%)
  Emphysema 8 (6%)
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Variable Population (n=124)
  Pleural Changes 7 (6%)
*
Age , FVC, FEV1, and TLC are presented as means with standard deviations (SD) . FEV1/FVC and Dlco are presented as medians with
interquartile ranges (IQR).
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Table 2
Patient characteristics and frequencies of CT findings according to smoking history
Ever Smoked
(n=38)
Never Smoked
(n=86)
P-value
Age (years) * 42 (13) 48 (8) 0.01
Gender
  Female 28 (74%) 54 (63%) 0.2
Race
  Caucasian 28 (74%) 77 (90%) 0.03
  African American 10 (26%) 9 (10%) 0.03
Obstructive Disease 10 (26%) 27 (31%) 0.6
Pulmonary Function (%) † *
  FVC 85 (21) 86 (18) 0.8
  FEV1 83 (22) 83 (24) 0.98
  FEV1/FVC 77 (70-82) 74 (66-78) 0.08
  TLC 88 (19) 89 (17) 0.7
  DLco 71 (55-83) 76 (66-88) 0.1
Treatment
    Total Treated 28 (74%) 66 (76%) 0.7
    CT scan prior to treatment 15 (40%) 28 (32%) 0.5
    Ongoing treatment during CT 11 (29%) 25 (29%) 1.0
    Completed treatment  2 (5%) 13 (15%) 0.1
    Reason for Treatment
    Pulmonary Disease  9 (24%) 40 (61%) 0.02
    Extrapulmonary Disease 19 (50%) 26 (39%) 0.03
    Type of Treatment
    Prednisone 24 (63%) 63 (73%) 0.3
    Methotrexate 17 (45%) 42 (49%) 0.7
    Inhaled Therapy 12 (32%) 39 (45%) 0.2
     Corticosteroid Only  2 (5%) 11 (13%) 0.3
     Bronchodilator Only  6 (16%)  6 (7%) 0.2
     Steroid and Bronchodilator  4 (11%) 22 (26%) 0.09
CT Findings
  Lymph Nodes 36 (95%) 75 (87%) 0.2
  Bronchiectasis 9 (24%) 20 (23%) 0.9
  Nodules 23 (61%) 60 (70%) 0.3
  Thickened BV Bundles 11 (29%) 50 (58%) 0.003
  Ground Glass 10 (26%) 13 (15%) 0.1
  Displaced Hilum 3 (8%) 10 (12%) 0.8
  Emphysema 7 (18%) 1 (1%) 0.001
  Alveolar Opacities 3 (8%) 12 (14%) 0.6
  Pleural Changes 0 (0%) 7 (8%) 0.1
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Ever Smoked
(n=38)
Never Smoked
(n=86)
P-value
  Fibrosis 9 (24%) 23 (27%) 0.8
*
Age , FVC, FEV1, and TLC are presented as means with standard deviations (SD) . Student’s t-tests were used for comparisons of these variables.
†
FEV1/FVC and Dlco are presented as median with interquartile range (IQR). Wilcoxon rank sum tests were used for comparisons of these
variables.
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Table 3
Characteristics of patients with the CT finding of bronchovascular bundle thickening
Thick BV Bundles
(n=61)
No Thick BV Bundles
(n=63)
P-value
Age (years) * 47 (13) 45 (9) 0.4
Smoking Status
  Current Active Smokers 4 (7%) 15 (24%) 0.008
  Ever Smoked† 11 (18%) 27 (43%) 0.003
  Never Smoked 50 (82%) 36 (57%) 0.003
Obstructed 25 (41%) 12 (19%) 0.008
Ever Treated 51 (84%) 43 (68%) 0.04
  Prednisone 48 (79%) 39 (62%) 0.05
  Methotrexate 30 (49%) 29 (46%) 0.9
  Inhaled Therapies 29 (48%) 22 (35%) 0.2
*
Age values are expressed as means with standard deviations (mean (SD)). Student’s t-tests were used for comparisons of this variable.
†
Includes those who are current active smokers and those who have smoked in the past.
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Table 4
Characteristics of obstructed and non-obstructed patients
Variable Non-Obstructed
(n=87)
Obstructed
(n=37)
P-value
Age (years) † 43 (11) 51 (10) 0.0008
Gender
  Female 57 (65%) 25 (68%) 0.8
Race
  African-American 17 (20%) 2 (5%) 0.06
  Caucasian 70 (80%) 35 (95%) 0.06
Smoking Status
  Never Smoked 59 (68%) 27 (73%) 0.6
  Ever Smoked 28 (32%) 10 (27%) 0.6
Obstructive Disease
Pulmonary Function (%) * †
  FVC 88 (20) 80 (16) 0.05
  FEV1 90 (20) 67 (18) <0.0001
  FEV1/FVC 78 (75-82) 64 (57-67) <0.0001
  TLC 87 (17) 92 (19) 0.3
  DLco 76 (60-84) 74 (65-88) 0.6
Asthma History  9 (10%)  7 (19%) 0.2
Obstructive Sleep Apnea  9 (10%)  7 (19%) 0.2
Treatment History
  Prednisone therapy 57 (65%) 30 (81%) 0.09
  Methotrexate 39 (45%) 20 (54%) 0.3
  Inhaled therapies 27 (27%) 24 (65%) 0.0005
    Steroid/Bronchodilator 14 (16%) 12 (32%) 0.04
    Corticosteroid  6 (7%)  7 (19%) 0.06
    Bronchodilator Only  7 (8%)  5 (14%) 0.3
CT Findings
  Lymph Nodes 79 (91%) 32 (86%) 0.5
  Nodules 53 (61%) 30 (81%) 0.03
  BVB Thickening 36 (41%) 25 (68%) 0.008
  Fibrosis 18 (21%) 14 (38%) 0.04
  Bronchiectasis 17 (20%) 12 (32%) 0.1
  Ground Glass 13 (15%) 10 (27%) 0.1
  Alveolar Opacities 8 (9%) 7 (19%) 0.1
  Displaced Hilum 5 (6%) 8 (22%) 0.02
  Emphysema 4 (5%) 4 (11%) 0.2
  Pleural Changes 5 (6%) 2 (5%) 0.9
*
Age , FVC, FEV1, and TLC are presented as means with standard deviations (SD) . Student’s t-tests were used for comparisons of these variables.
Acad Radiol. Author manuscript; available in PMC 2012 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Gerke et al. Page 16
†
FEV1/FVC and Dlco are presented as median with interquartile range (IQR). Wilcoxon rank sum tests were used for comparisons of these
variables.
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